Clinical benefit of lapatinib-based therapy in patients with HER2-positive breast tumors co-expressing the truncated p95HER2 receptor

PURPOSE: A subgroup of HER2 overexpressing breast tumors co-expresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Scaltriti, Maurizio, Chandarlapaty, Sarat, Prudkin, Ludmila, Aura, Claudia, Jimenez, José, Angelini, Pier Davide, Sánchez, Gertrudis, Guzman, Marta, Parra, Josep Lluis, Ellis, Catherine, Gagnon, Robert, Koehler, Maria, Gomez, Henry, Geyer, Charles, Cameron, David, Arribas, Joaquin, Rosen, Neal, Baselga, José
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3243489/
https://ncbi.nlm.nih.gov/pubmed/20406840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-3407
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi